Abstract:Background: Cells showed highly plasticity in the process of EMT. Cells dedifferentiation and remodeling to promote wound healing or fibrosis. Tumor cells acquired migratory, invasive, and stem-like properties after EMT. Microenvironment plays a major regulatory role in EMT to influence cell plasticity. Take advantage of the plasticity of cells undergo EMT to induce cell trans-differentiation is a new research direction.Methods: In this study we used transforming growth factor (TGF-β), epidermal growth factor (EGFR) inhibitor and the combination to treat hepatocellular carcinoma (HCC). Cells morphology was observed, the expression of cell surface markers, fibrosis-related proteins were detected, the ability of proliferation, invasion, and migration in HCC were measured. Key molecules were found by RNA sequencing and PPI network construction and verified.Findings: We found that after combination treatment with EGFR inhibitor and TGF-β, HCC showed low malignancy and fibroblastic properties. We generated interactions between proteins (PPI) network of differentially expressed genes (DEGs), and found that RUNX2 played an important role in the process. After RUNX2 inhibitor to cancel the role of RUNX2, the cell morphology gradually returned to normal from a long spindle shape in both TGF-β group and TGF-β combined EGFR inhibitor. And fibroblast phenotypic marker and fiber-related protein expression were down-regulated.Interpretation: Our data indicated that TGF-β combined EGFR inhibitor could induce HCC trans-differentiated into fibroblast by influencing EMT and RUNX2 have the key role in the process. Our results provide us with a new direction in cancer trans-differentiation.Funding Statement: This work was supported by the National Natural Science Foundation of China (81473441) and the Program for New Century Excellent Talents in University (NO.NCET-11-1068).Declaration of Interests: The authors declared that they have no conflicts of interest to this work.Ethics Approval Statement: Mice were obtained from the Beijing Vital River Experimental Animal Technical Company and used in accordance with the Animal Ethical and Welfare Committee of Tianjin Medical University Cancer Institute and Hospital (2018098).

EGFR Mediates Epithelial‑mesenchymal Transition Through the Akt/GSK-3β/Snail Signaling Pathway to Promote Liver Cancer Proliferation and Migration.

Infiltrating Regulatory T Cells Promote Invasiveness of Liver Cancer Cells Via Inducing Epithelial-Mesenchymal Transition

EGF is Highly Expressed in Hepatocellular Carcinoma (HCC) and Promotes Motility of HCC Cells Via Fibronectin.

The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.

CXCR2/CXCL5 Axis Contributes to Epithelial–mesenchymal Transition of HCC Cells Through Activating PI3K/Akt/GSK-3β/Snail Signaling

FGF 19 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells by Modulating the GSK 3 Β / Β-Catenin Signaling Cascade Via FGFR 4 Activation

CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.

Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial To Mesenchymal Transition In Hepatocellular Carcinoma Cells

EDG2 Enhanced the Progression of Hepatocellular Carcinoma by LPA/PI3K/AKT/ Mtor Signaling.

PD‐L1 regulates epithelial–mesenchymal transition and cancer stem cell phenotypes in Hepatocellular Carcinoma through SGK2/β‐catenin signaling pathway

TGF-β Combined with EGFR Inhibitor Induce HCC Trans-Differentiation into Fibroblasts Via Epithelial-Mesenchymal Transition

FGG Promotes Migration and Invasion in Hepatocellular Carcinoma Cells Through Activating Epithelial to Mesenchymal Transition.

Glypican-3 Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells Through Erk Signaling Pathway

Involvement of the Epidermal Growth Factor Receptor in the Modulation of Multidrug Resistance in Human Hepatocellular Carcinoma Cells in Vitro

Downregulation of Epidermal Growth Factor Receptor in hepatocellular carcinoma facilitates Transforming Growth Factor-β-induced epithelial to amoeboid transition

Liver Cancer: Ephrina2 Promotes Tumorigenicity Through Rac1/Akt/Nf-Kappa B Signaling Pathway

LncRNA SNHG12 promotes proliferation and epithelial mesenchymal transition in hepatocellular carcinoma through targeting HEG1 via miR-516a-5p

HCRP1 Downregulation Promotes Hepatocellular Carcinoma Cell Migration and Invasion Through the Induction of EGFR Activation and Epithelial-Mesenchymal Transition.

Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma

EPS8L3 Promotes Hepatocellular Carcinoma Proliferation and Metastasis by Modulating EGFR Dimerization and Internalization.

Inhibition of ERK1/2 Signaling Impairs the Promoting Effects of TGF-β1 on Hepatocellular Carcinoma Cell Invasion and Epithelial-Mesenchymal Transition.